Astellas Pharma (4503) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
18 Sep, 2026Executive summary
Revenue grew 27% year-on-year to ¥640.9 billion, and core operating profit rose 56% to ¥221.4 billion, both reaching record highs for the first quarter, driven by strong performance of strategic brands and disciplined cost optimization, aided by favorable FX impacts.
Strategic brands PADCEV, IZERVAY, VYLOY, VEOZAH, and XOSPATA delivered robust growth, with PADCEV and IZERVAY sales up 36% and 70% year-on-year, respectively.
Pipeline advanced with multiple regulatory approvals and filings for PADCEV in muscle-invasive bladder cancer, and significant progress in Phase 3 studies for VYLOY and other assets.
Profit attributable to owners of the parent more than doubled to ¥141.8 billion, with basic earnings per share up 107.1% to ¥79.15.
Financial highlights
Q1 revenue reached ¥640.9 billion (+26.7% year-on-year), with FX contributing ¥60.0 billion.
Core operating profit was ¥221.4 billion (+55.6% year-on-year), with a margin of 34.5%.
Operating profit and net profit more than doubled year-on-year; comprehensive income surged 426.2% to ¥183.6 billion.
SG&A expenses rose 9.2% to ¥215.1 billion, and R&D expenses increased 14% to ¥81.7 billion.
Revenue increased across all regions, notably 28.5% in the US and 60.5% in International Markets.
Outlook and guidance
Full-year FY2026 revenue forecast is ¥2,220.0 billion (+3.8% year-on-year), with core operating profit expected at ¥620.0 billion (+11.6%).
Strategic brands expected to further drive revenue and profit growth in subsequent quarters.
Increased R&D investment anticipated as clinical trials progress, balanced with continued cost discipline.
Dividend per share forecast raised to ¥80.00 for FY2026.
FX sensitivity: every ¥1 depreciation in USD or EUR adds approximately ¥8.1 billion and ¥3.8 billion to revenue, respectively.
Latest events from Astellas Pharma
- Raised FY2026 outlook supports a pivot to pipeline-led growth from FY2029.4503
Investor presentation - FY26 margin target pulled forward as pipeline-led growth builds beyond XTANDI.4503
Jefferies Global Healthcare Conference - Strategic Brand growth lifts FY2026 core operating profit guidance to ¥700bn.4503
Q2 2027 - Sustainability efforts and governance reforms are driving measurable enterprise value and innovation.4503
Sustainable Meeting 2024 - Pipeline-led growth, high-margin brands, and oncology innovation to drive record revenues.4503
Jefferies Global Healthcare Conference 2026 - Record revenue and profit growth driven by Strategic Brands and cost optimization, with strong FY2026 outlook.4503
Q4 2026 - Double-digit revenue and profit growth led to upward guidance, driven by strategic brands.4503
Q3 2026 - Core operating profit surged 54.4% on 10.1% revenue growth and strong brand sales.4503
Q2 2026 - Q1 revenue up 26.2% year-on-year, driven by XTANDI and strategic brands, with strong profit growth.4503
Q1 2025